In our new report Launch Readiness 2022, we consider how launch strategists may best navigate a fast-changing yet still commercially ripe environment for pharmaceutical launch readiness. We show how digital transformation and cutting-edge launch management software help companies track the status of launch activities and manage global launch challenges, in real-time and across both functions and countries.
New Report: Launch Readiness 2022 - How to address key trends and challenges
Topics: launch readiness, launch strategy, launch effectiveness, launch readiness framework, launch plan, pharma tenders
Rethinking Launch Readiness in 2021: The New Normal in the Shadow of COVID
It is probably reasonable enough by now to talk about the launch readiness landscape for medicines and vaccines as pre- and post-COVID. We can also say with some certainty that nothing will ever be the same again.
Topics: launch readiness, launch strategy, launch effectiveness, launch readiness framework, launch plan, pharma tenders
Pharmaceutical companies have more reasons than ever to hone their launch readiness skills. The question is whether they possess the new product launch strategies and tools to successfully commercialise their new medicines in an often volatile and always competitive global marketplace.
Topics: launch readiness, launch strategy, launch effectiveness, launch readiness framework, launch plan, pharma tenders
Access to medicines is a loaded term. In an ideal world, every patient would have unimpeded access to the best drug available. In reality, access is usually selective at best.
Topics: patient access, launch effectiveness